Loading... (0%)
About liver disease

Press releases

GENFIT: Half-Year report of Liquidity Contract with CIC
Published on: 07/05/2018
GENFIT: New Preclinical Data Shows Elafibranor Inhibits Development of NAFLD/NASH-Related Cancer
Published on: 06/27/2018
GENFIT: Outcome of the Ordinary and Extraordinary Shareholders’ Meeting of June 15, 2018
Published on: 06/18/2018
GENFIT: Announces the Nomination of Pascal Prigent as Executive Vice President Marketing and Commercial Development
Published on: 05/31/2018
GENFIT: Ordinary and Extraordinary Shareholders’ Meeting of june 15, 2018 – Availability of Preparatory Documents
Published on: 05/09/2018
GENFIT: Publication of the 2017 Registration Document
Published on: 04/27/2018
GENFIT: First quarter 2018 financial information
Published on: 04/27/2018
GENFIT: Positive Outcome from the 24-month Pre-Planned Safety Review by the DSMB, in RESOLVE-IT Phase 3 Clinical Trial with Elafibranor
Published on: 04/23/2018
GENFIT: Major Milestone for the RESOLVE-IT Phase 3 Trial on the Recruitment of the Interim Analysis Cohort
Published on: 04/11/2018
GENFIT: Presentations at EASL 2018 Annual Congress Highlight Progress in NASH Diagnostics, Combination Therapies and Deep-learning Applications in Medical Imaging
Published on: 03/28/2018
  • Shareholders Letter
    N°8, October 2017
Corporate information
  • Analyst/Investor presentation
    October 2017
Financial information

If you want to contact our Press Relations team, please do not hesitate to send us a message.

Contact us